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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.07.009Objective: The optimal diameter at which replacement of the ascending aorta should
be performed in patients with bicuspid aortic valve disease is not known.
Methods: We reviewed all patients with bicuspid aortic valves undergoing aortic
valve replacement at our institution from 1979 through 1993 (n  201). Patients
undergoing concomitant replacement of the ascending aorta were excluded.
Results: Follow-up was obtained on 98% of patients and was 10.3  3.8 (mean
 SD) years. The average patient age was 56  15 years, and 76% were male.
The ascending aorta was normal (4.0 cm) in 115 (57%) patients, mildly dilated
(4.0-4.4 cm) in 64 (32%) patients, and moderately dilated (4.5-4.9 cm) in 22
(11%) patients. All patients with bicuspid aortic valves with marked dilation
(5.0 cm) underwent replacement of the ascending aorta and were therefore
excluded. Fifteen-year survival was 67%. During follow-up, 44 patients required
reoperation, predominantly for aortic valve prosthesis failure. Twenty-two pa-
tients had long-term complications related to the ascending aorta: 18 required an
operative procedure to replace the ascending aorta (for aortic aneurysm), 1 had
aortic dissection, and 3 experienced sudden cardiac death. Fifteen-year freedom
from ascending aorta–related complications was 86%, 81%, and 43% in patients
with an aortic diameter of less than 4.0 cm, 4.0 to 4.4 cm, and 4.5 to 4.9 cm,
respectively (P  .001).
Conclusions: Patients undergoing operations for bicuspid aortic valve disease
should be considered for concomitant replacement of the ascending aorta if the
diameter is 4.5 cm or greater.
Aortic valve replacement is the therapy of choice for patients withsymptomatic aortic valvular disease. Severe aortic valve disease isoccasionally associated with dilation of the ascending aorta. Cur-rent recommendations call for surgical replacement of ascendingaortic aneurysms if they exceed 5.5 cm in diameter or 5.0 cm inpatients with Marfan syndrome.1
Patients with bicuspid aortic valve disease are at increased risk of aneurysms of
the ascending aorta, aortic dissections, and rupture. The increased risk might be due
to hemodynamic factors or to a genetic predisposition.2 The purpose of this study
was to describe the risk of future aortic complications in patients undergoing aortic
valve replacement for bicuspid disease and to determine the threshold diameter for
which the ascending aorta should be replaced.
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Ethics approval was granted by our institutional research ethics
board. Our computerized database was examined to identify all
patients undergoing aortic valve replacement for bicuspid aortic
valve (BAV) disease. The vast majority of patients with BAV
disease had one valve cusp that was attached to less than one half
of the annulus and one cusp that was attached to more than one
half of the annulus, with a raphe between the 2 fused leaflets.
Rarely, patients with BAV disease had 2 equal-sized cusps with no
raphe and coronary ostia that were 180° apart (true bicuspid
disease).3
We included patients operated on by one surgeon (T.E.D.) to
obtain consistent descriptions of pathologies of the aortic valve
and ascending aorta. All patients with BAV disease undergoing
aortic valve replacement with or without coronary bypass or other
valvular procedures between 1979 and 1993 were included. Pa-
tients undergoing surgical intervention after 1993 were excluded to
TABLE 1. Preoperative and intraoperative demographics
for patients with bicuspid aortic valve disease undergoing
aortic valve replacement from 1979 through 1993 (n  201)
Variable Prevalence*
Age (y) 56 15
Body surface area (m2) 1.85  0.21
Male sex 76%
Hypertension 25%
LV ejection fraction 40% 19%
NYHA class III or IV 51%
Congestive heart failure 34%
Urgent timing 15%
Reoperation 3%
Endocarditis 6%
Diabetes mellitus 6%
Mitral valve surgery 8%
Tricuspid valve surgery 1%
Coronary bypass surgery 32%
Aortic crossclamp time (min) 66 25
CPB time (min) 86 29
LV, Left ventricular; NYHA, New York Heart Association; CPB, cardiopul-
monary bypass.
*Continuous variables are expressed as means  SD.
TABLE 2. Perioperative outcomes for patients with bicus-
pid aortic valve disease undergoing aortic valve replace-
ment from 1979 through 1993 (n  201)
Outcome Prevalence*
Myocardial infarction 1%
Intra-aortic balloon pump 6%
Low cardiac output syndrome 15%
Stroke 1%
Hospital stay (d) 6.8 6.8
Mortality 2.5%
*Continuous variables are expressed as means  SD.obtain adequate long-term follow up. Patients with BAV disease
678 The Journal of Thoracic and Cardiovascular Surgery ● Noveundergoing aortic root replacement (the Bentall procedure, n 20)
or supracoronary replacement of the ascending aorta (n 21) were
also excluded. A total of 201 patients were available for the final
analysis.
Aortic valve replacement was performed with previously de-
scribed techniques.4,5 All patients underwent cardiopulmonary by-
pass with mild-to-moderate systemic hypothermia. Antegrade
crystalloid cardioplegia was used before 1989, and antegrade
blood cardioplegia has been used since. The aortic annulus was
enlarged in patients with a small annulus, according to previously
described techniques.6
The ascending aorta was measured intraoperatively by means of
direct measurement, transesophageal echocardiography, or both. All
measurements referred to in this study are of the ascending aorta and
not the aortic root. Operative reports for all patients were examined to
determine the diameter of the ascending aorta during the aortic valve
replacement surgery. The size of the ascending aorta was determined
from precise intraoperative measurements in 78% of patients and by
means of semiquantitative assessment in 22%. For those patients who
did not have exact measurements recorded, we used the following
guidelines. First, if the ascending aorta was reported as normal, it was
recorded as having a diameter of less than 4 cm. Second, if the
ascending aorta was reported as “mildly dilated,” it was recorded as
having a diameter of 4.0 to 4.4 cm. Third, if the ascending aorta was
reported as “moderately dilated,” it was recorded as having a diameter
TABLE 3. Causes of reoperation and death during long-
term follow-up in patients undergoing aortic valve replace-
ment for bicuspid disease
Outcome n
Reoperation
SVD 28
Aortic aneurysm 7
Endocarditis 3
Pannus formation 2
Aortic dissection 1
Mitral regurgitation 1
LVOT obstruction 1
Heart transplant 1
Total 44
Cardiac death
Congestive heart failure 10
Myocardial infarction 8
Valve related 5
Sudden death 3
Noncardiac death
Cancer 11
Renal failure 2
Pneumonia 2
COPD 1
Elderly age 1
Total death 43
SVD, Structural valve deterioration (includes 11 patients who underwent
concomitant replacement of the ascending aorta); LVOT, left ventricular
outflow tract; COPD, chronic obstructive pulmonary disease.of 4.5 to 4.9 cm. Patients with ascending aortas that were “severely
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were not part of this study.
Follow-up was obtained by means of telephone and mail ques-
tionnaire of patients, family members, or both. Echocardiography
reports were obtained from the patients’ cardiologists and family
physicians. Operative reports were obtained on all patients who
required reoperation during follow-up.
Categoric variables are expressed as percentages, and continu-
ous variables are expressed as means  SD throughout the article.
All statistical analyses were performed with the SAS system (SAS
version 8.1, Cary, NC). Comparison of categoric variables was
performed with 2 or Fisher exact tests, and continuous variables
were analyzed with 1-way analysis of variance. Long-term sur-
vival and event-free survival were analyzed with the methods of
Kaplan-Meier. Comparisons between groups were compared with
the log-rank test.
Results
A total of 201 patients with BAV disease underwent aortic
valve replacement during the study period. Aortic valve
repair was not performed in any patients. Table 1 displays
the preoperative and intraoperative demographics for the
entire group.
Of the 201 patients with BAV disease, 63% had aortic
stenosis, 22% had aortic regurgitation, and 15% had a
mixed lesion. One patient had associated Marfan syndrome
with a normal-sized ascending aorta.
The aortic valve was replaced with a stented tissue valve
in 60% of patients, a stentless tissue valve in 18%, a
mechanical valve in 12%, a pulmonary autograft in 7%, and
a homograft in 3%. The labeled valve size was 19 in 1% of
patients, 21 in 6%, 23 in 16%, 25 in 22%, 27 in 39%, and
29 in 16%.
Perioperative outcomes for the entire group of patients
are listed in Table 2. The in-hospital mortality was 2.5% (5
patients).
Follow-up was obtained on 98% of patients. The mean
( SD) length of follow up was 10.3 3.8 years. A total of
43 (21%) patients died during follow-up. Ten- and fifteen-
year survival was 81%  3% and 67%  4%, respectively.
TABLE 4. Comparison of variables that affect future aortic d
those with mild or moderate dilation at the time of aortic
Variable
<4 cm
(n  115)
Age (y) 55 15
Male sex 75%
Hypertension 26%
Aortic valve pathology
Stenotic 64%
Insufficiency 23%
Mixed 12%Forty-four (22%) patients required reoperation during
The Journal of Thoracifollow-up. The causes of reoperation and death are summa-
rized in Table 3.
At the time of initial aortic valve replacement surgery,
the ascending aorta was normal sized (4 cm) in 115 (57%)
patients, mildly dilated (4.0-4.4 cm) in 64 (32%) patients,
and moderately dilated (4.5-4.9 cm) in 22 (11%) patients.
As stated previously, patients with ascending aortic diame-
ters of 5 cm or more underwent replacement of the aorta and
therefore were not included in this study. The 3 groups of
patients were similar for those variables that are known to
have an effect on future dilation of the ascending aorta: age,
sex, hypertension, and valve pathology (Table 4).
Figure 1 displays the Kaplan-Meier survival curves for
these 3 groups of patients. Patients with moderate dilation of
the ascending aorta (4.5-4.9 cm) had worse long-term sur-
vival than the other 2 groups (P  .004, log-rank test).
Ascending aortic complications occurred in 22 patients
during follow-up: 18 had an aneurysm requiring replace-
ment of the ascending aorta, 1 had an aortic dissection
requiring emergency surgical intervention, and 3 experi-
enced sudden cardiac death. Of the 18 patients who had an
ascending aortic aneurysm, 7 underwent isolated replace-
ment of the aorta, and 11 underwent simultaneous aortic
valve replacement for structural valve deterioration. The
average size of the ascending aorta during replacement
surgery was 58  9 mm.
Figure 2 displays the Kaplan-Meier curves for freedom
from ascending aortic complications according to the 3
groups of patients. Patients with an ascending aortic diam-
eter of 4.5 cm or greater had a significantly increased risk of
future aortic complications (P  .001).
Discussion
BAV disease is the most common congenital cardiac anom-
aly and is seen in 1% to 2% of the population.7 A large
pathologic review by Sabet and colleagues3 revealed that
BAV disease results in a stenotic lesion in three quarters of
patients, insufficiency in 15%, and a mixed lesion in 10%,
ion in patients with normal ascending aorta diameters and
e replacement surgery
.0–4.4 cm
(n  64)
4.5–4.9 cm
(n  22) P value
56  15 61 10 .2
72% 91% .2
23% 27% .9
61% 64% .7
19% 23%
20% 14%ilat
valv
4results that are similar to ours.
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dilation, aneurysm formation, dissection, and rupture.8,9
The cause of ascending aortic dilation in such patients is
unknown. A hemodynamic flow disturbance in the aorta
beyond the stenotic valve is one possible cause of dilation
because this mechanism is also observed in patients with
stenotic tricuspid valves. The second possibility is a genetic
predisposition to aortic dilation in patients with BAV dis-
ease. An increasing amount of data has been reported to
support this latter cause.
Several investigators have found that patients with BAV
disease, including those with a hemodynamically normal
valve, have dilated aortic roots and ascending aortas com-
Figure 1. Kaplan-Meier survival curves for patients with BAV
disease with an ascending aortic diameter of less than 4 cm, 4.0
to 4.4 cm, and 4.5 to 4.9 cm at the time of aortic valve–replace-
ment surgery. Patients with moderate dilation of the aorta (4.5-4.9
cm) had significantly worse long-term survival.
Figure 2. Freedom from ascending aortic complications for pa-
tients with BAV disease. Patients with moderate dilation of the
ascending aorta (4.5-4.9 cm) had a significantly increased risk of
future aortic complications (aneurysm, dissection, or sudden
death).pared with age- and sex-matched control subjects.10-12 In
680 The Journal of Thoracic and Cardiovascular Surgery ● Noveaddition, there is a high correlation between coarctation of
the aorta and BAV disease.2,9,10 The close association raises
the possibility that such patients have congenitally increased
fragility of the aortic media, which might in turn lead to
dilation of the ascending aorta. Further evidence for a ge-
netic component lies in the fact that BAV disease seems to
follow an autosomal dominant inheritance pattern with re-
duced penetrance.13,14 Histologic studies have also con-
firmed that patients with BAV disease have abnormalities of
the aortic media. Our group has previously demonstrated
decreased fibrillin 1 content and increased matrix metallo-
proteinase 2 activity in the aortic media of patients with
BAV disease when compared with levels seen in patients
with tricuspid valves.15 In addition, we found increased
severity of cystic medial necrosis, elastic fragmentation, and
smooth muscle cell reorientation in patients with BAV
disease.16 Bauer and coworkers17 also demonstrated that
patients with BAV disease have thinner elastic lamellae of
the aortic media and greater distances between elastic la-
mellae than patients with tricuspid aortic valves.
Given that patients with BAV disease have more abnor-
malities of the aortic media and are predisposed to ascend-
ing aortic dilation, we attempted to determine the optimal
diameter for ascending aortic replacement during aortic
valve surgery. We identified 201 patients with BAV disease
who underwent aortic valve replacement between 10 and 25
years ago. Not surprisingly, patients with BAV disease were
younger (mean age, 56 years) than most patients undergoing
aortic valve replacement and were predominantly male.
Because of their young age, long-term survival of patients
with BAV disease was much higher (67% at 15 years) than
survivals seen in most aortic valve–replacement series.
Patients were divided into 3 groups in our study, accord-
ing to the size of the ascending aorta at the initial operation.
We have traditionally used an aggressive approach to the
ascending aorta in patients with BAV disease, with routine
replacement if the aorta measures 5 cm or more in diameter.
Therefore such patients were excluded from the current
study.
The 3 groups of patients were similar for all preoperative
characteristics, including age, sex, prevalence of hyperten-
sion, and aortic valve pathology–factors that affect future
dilation of the aorta (Table 4). Despite these similarities,
patients with moderate aortic dilation (4.5-4.9 cm) had a
significantly increased risk of long-term aortic complica-
tions, including aneurysm, dissection, or sudden death (Fig-
ure 2). In addition, these patients had lower long-term
survivals compared with patients with no or mild aortic
dilation (Figure 1).
Our findings would suggest that the ascending aorta
should be replaced in patients with BAV disease with an
aortic diameter of 4.5 cm or more undergoing aortic valve
surgery. Surgeons should therefore consider valve pathol-
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whether to replace the ascending aorta. Supportive evidence
for this strategy can be found in a study by Russo and
associates.18 These investigators compared long-term out-
comes in patients with tricuspid versus bicuspid aortic
valves undergoing valve replacement surgery. The inci-
dences of late aortic dissection, sudden death, and cardiac-
related death were significantly higher in patients with BAV
disease. In addition, echocardiography of all long-term sur-
vivors revealed that the ascending aorta was significantly
larger in patients with bicuspid valves than in patients with
tricuspid valves (mean, 48 vs 37 mm).
Before recommending routine replacement of the as-
cending aorta in patients with BAV disease, we must first
examine the surgical options. Operative strategies, in
increasing order of complexity, consist of the following:
(1) aortic valve replacement only (ie, leaving the ascend-
ing aorta intact), (2) reduction aortoplasty with or with-
out reinforcement of the aorta, (3) replacing the supra-
coronary ascending aorta with a separate tube graft, and
(4) replacing the entire aortic root and ascending aorta
with reimplantation of the coronary ostia (ie, the Bentall
procedure).19,20 The risk of long-term aortic complica-
tions for less complex procedures must be balanced
against the increased perioperative risk associated with
more complex procedures. Reduction aortoplasty is less
technically demanding than tube graft replacement of the
ascending aorta, but long-term results reveal a significant
risk of recurrent dilation.20,21 We have therefore avoided
this procedure. The operative mortality for Bentall pro-
cedures at our institution over the last 5 years is 3.9%.
Although this risk is relatively small, it is significantly
higher than that for isolated aortic valve replacement
over the same time period (1.8%, P  .01).
Study Limitations
One limitation of our study is that the size of the ascending
aorta during the initial aortic valve operation was assessed
in a semiquantitative manner in 22% of patients, predomi-
nantly during earlier years of the study. It would have been
preferable to obtain exact measurements of the ascending
aorta and root at the time of the initial operation in these
patients. The same surgeon, however, assessed all patients,
and we therefore believe that our semiquantitative measure-
ments were consistent.
Another limitation of our study is its retrospective
design. Randomizing patients with BAV disease to re-
ceive aortic valve replacement plus or minus replacement
of the ascending aorta would supply us with the definitive
answer to our hypothesis, but this is unlikely to occur in
the foreseeable future. We believe our study is the best
available method of assessing this clinical issue at this
time.
The Journal of ThoraciSummary
The current study demonstrates that patients with BAV
disease with moderate dilation of the ascending aorta (4.5-
4.9 cm) have a significantly higher risk of long-term aortic
complications. Consideration should be given to replacing
the ascending aorta if it is more than 4.5 cm in diameter in
patients with BAV disease.
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Discussion
Dr Ludwig K. von Segesser (Lausanne, Switzerland). I congrat-
ulate Dr Borger and colleagues for this interesting report. The main
issue here is what to do with borderline aortic dilatation, and a
number of approaches have been proposed for this: let it be (we
now know that some patients come back); aggressive replacement
(at the cost of a higher risk); reduction aortoplasty (we have shown
in the past that some patients come back, too); and reduction
aortoplasty with external support, as reported by Francis Robicsek
in the 1970s.
Dr Robicsek would use a Dacron graft for external support. In
the old days, Ake Senning just went to the local department store,
bought some nylon curtain, sterilized it, and used it. He probably
even reused the part that was not used for the primary procedure.
Nowadays, we use routinely a polyester net, as for hernia surgery,
which might be an off-label use over here. I have a few questions.
Was there a difference between the 4.4- and 4.9-cm groups?
Dr Borger. In terms of long-term complications?
Dr von Segesser. Yes.
Dr Borger. What we did is we split the 2 patients into 2 groups
because we were dealing with a relatively small number of pa-
tients, and therefore I cannot answer that question for you specif-
ically. But I do know that the rate of aneurysm expansion is higher
in patients with a larger aorta. Therefore intuitively I would say
that, yes, there must be more long-term aortic complications in the
4.9-cm patients than in the 4.4-cm patients.
Dr von Segesser. Can you tell us something about wall quality
and how this affects the operating strategy?
Dr Borger. These are patients from 1979 through 1993, and I
think Dr David was pretty aggressive back then in his treatment of
dilated aortas in bicuspid patients. However, I would say we are
now even a little more aggressive in the treatment of this disease.
If the aortic wall is very thin, even if it is not excessively dilated,
we are currently more likely to replace it.
Dr von Segesser. Would you handle a dilated aorta in the same
way as a dilated and very elongated aorta in which the heart is
pushed into the left chest?
Dr Borger. We would make the decision to replace the aorta on
the basis of its diameter only and not its length. The only alteration
we make for a patient with a long aorta is that if we do replace it
(on the basis of its diameter), then we make the replacement graft
much shorter than the original aorta to try to get the heart back up
into a more physiologic position.
Dr von Segesser. And my last question is whether there is a
correlation between body size or surface area and aortic compli-
cations.
Dr Borger. No, there was not. We looked at that and were
unable to find an association.
Dr von Segesser. So you think that, let us say, a 35-kg old
woman with a 4-cm diameter should be addressed in the same way
as a 2.5-m2 member of the National Hockey League?
Dr Borger. No, I do not, and I am going to give you a long
answer to that question. We are not trying to say to all surgeons
that 4.0 cm is the magic number and that you should replace the
aorta in all patients with bicuspid valves with even mild aortic
682 The Journal of Thoracic and Cardiovascular Surgery ● Novedilation. What we are trying to say is that we should consider valve
pathology (ie, tricuspid vs bicuspid disease) when making our
decision whether to replace the aorta. Our data would suggest that
we should lower our threshold for ascending aortic replacement in
bicuspid patients. The surgeon has to consider many other factors,
including patient age, comorbidities, type of valve prosthesis, and
surgeon-specific results, when deciding whether to replace the
aorta. An example would be a 30-year-old patient with bicuspid
disease who has a 42-mm ascending aorta in whom you are going
to insert a mechanical prosthesis because the patient wants to avoid
future reoperations. I think 20 years ago it would have been
unheard of to replace the ascending aorta in this patient. However,
our data might suggest that you can do a full Bentall procedure in
this patient to try to limit the risk of future reoperation or other
complications of the aorta. Therefore the decision to replace the
ascending aorta is patient specific and, to a certain extent, surgeon
specific.
Dr Christophe Acar (Paris, France). Dr Borger, I enjoyed
your presentation. Could you tell us what would be your recom-
mendations concerning the diameter of the ascending aorta above
the sinotubular junction? In patients with bicuspid aortic valve
stenosis, oftentimes the root is not dilated, and the only portion to
be enlarged is the supracoronary portion.
Dr Borger. That is a very good question, and we often see that
pathology in patients with tricuspid aortic stenosis. We do not
advocate a total root replacement in such patients but rather an
aortic valve replacement with concomitant replacement of the
supracoronary aorta. In patients with bicuspid aortic valves with
dilation of the aorta above the sinotubular junction, I believe
replacement of the supracoronary aorta is also the only operation
that is required. However, if it is a very young patient receiving a
mechanical valve and you are confident with the procedure, then a
full Bentall procedure might be the appropriate solution for that
patient.
Dr Acar. And a 4-cm diameter would be measured at which
level, the level of the sinuses or the level of the ascending aorta
above the sinotubular junction?
Dr Borger. Above the sinotubular junction, the ascending
aorta.
Dr Acar. It would be 4 cm, the same.
Dr F. W. Mohr (Leipzig, Germany). Michael, I fully agree
with the conclusions. What about patients with bicuspid disease in
whom you’ve decided to replace the ascending aorta and also
require coronary artery bypass surgery? How about proximal graft
anastomosis in these cases? Do you completely avoid it? What is
the strategy? Can you comment on that?
Dr Borger. Dr David is very good at imparting his knowledge
on the other surgeons at our institution, and it is because of this that
we try to avoid proximal vein graft anastomoses to the Dacron
graft if the veins are of small caliber. Small-diameter vein grafts
have an increased risk of intimal hyperplasia at the anastomotic
site, probably in reaction to the Dacron. If the vein graft is of a
large diameter, then we will proceed with the usual proximal
anastomosis. The best option is to avoid proximal anastomoses
altogether, which we will do if possible.
Dr Richard J. Shemin (Boston, Mass). This was a very nice
paper. I am particularly interested in the patients requiring reop-
eration. Were any of these just for the primary indication of
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ascending aortic aneurysm, or was it the reoperation group deter-
mined by the ascending aortic pathology in addition to having
structural valve determination? What is the true denominator?
Dr Borger. Of the 28 that were operated on for structural valve
deterioration, 11 of them also had replacement of the ascending
aorta because of an aortic aneurysm. These patients were therefore
included in our composite outcome.
Dr Shemin. If you look back at this group, which is a signif-
icant number of the reoperations, if they did not have structural
deterioration of the valve, would the aorta alone have been the
indication for a reoperation?
Dr Borger. I cannot say definitely that the primary indication
for reoperation was structural valve deterioration in patients who
also underwent replacement of the aorta. But I can say that the
ascending aorta was definitely aneurysmal in these patients and
might have therefore been an indication for surgical intervention in
and of itself. In addition, there were 7 patients who presented with
ascending aortic aneurysms and normally functioning valve pros-
theses requiring isolated replacements of the aorta.
Dr Shemin. But you understand the implications of the ques-
tion. The final thing regards bicuspid valves: What is your recom-
mendation on the use of the Toronto valve in that subset of patients
in which there is the potential for further aortic dilatation?
Dr Borger. I think that it would be acceptable to use the
stentless Toronto valve if you perform some sort of reinforcement
of the sinotubular junction to prevent future dilation or if you are
using it in an elderly patient. I would not suggest the Toronto valve
for a young patient with a bicuspid valve without some sort of
reinforcement of the sinotubular junction.
Dr Bruce Lytle (Cleveland, Ohio). I have a question, but first
I would like to male a comment. The idea that you are going to do
a Bentall procedure with a mechanical prosthesis for a young man
and he never is going to have to have another operation is a lovely
thought, but experience thus far has not borne that out. The second
thing is that you really have 4 catastrophic events that happened if
you consider that all of the sudden deaths are related to an aortic
complication. Therefore over 10 years that means that you have
about a 0.2% per year risk of a catastrophe in these patients. It is
good to avoid that, but that must mean, of course, that the incre-
The Journal of Thoracimental risk of replacing the aorta also has to be extremely low.
Would you agree?
Dr Borger. I agree with that completely and would like to
reinforce what I previously stated. The take-home message from
this presentation is not that all 4-cm aortas should be replaced in
bicuspid patients. Rather, we would like surgeons to consider
aortic valve pathology as one of the factors when deciding whether
to replace the aorta in individual patients. We have been using an
aggressive approach to the ascending aorta for several years at our
institution. In some other institutions, the surgeons are much less
aggressive, and an ascending aorta of 5.5 cm might be left alone.
What I am trying to say is that you should probably re-evaluate this
strategy in patients with bicuspid aortic valve disease. We are
trying to lower the threshold a little in such patients.
At our hospital, the operative mortality rate for Bentall proce-
dures is 3.9% over the last 5 years. Although this rate is quite
acceptable, it is significantly higher than our mortality rate for
aortic valve replacement, which is 1.8%. Therefore there is an
absolute risk increase of 2% involved with a more aggressive
approach to this disease.
Dr Lytle. Putting into your risk catastrophic events during a
10-year follow-up.
Dr Claudio Muneretto (Brescia, Italy). I enjoyed your
paper. Of course the diameter of the aorta is a major concern in
surgical decision making. But are there any other important
concerns? For example, a positive family history for sudden
death could be considered, and did you look at this risk factor
in your analysis?
Dr Borger. We did not. I did not have that particular risk factor
in our database. I can tell you that we had only 22 outcomes of
interest, and we therefore did not feel justified in doing a Cox
proportional hazard analysis on our data. But I also can tell you
there was a paper from Russo and colleagues in Italy showing
essentially the same results as ours. These investigators performed
echocardiography on patients with tricuspid and bicuspid aortic
valves 10 years after their operations, and the bicuspid patients had
an average ascending aortic diameter of 48 mm versus 37 mm in
the tricuspid patients. In addition, the bicuspid patients had more
catastrophic complications, including aortic dissection and sudden
death. Therefore there are some long-term implications to not
replacing the aorta in bicuspid patients.
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